Suggestions
Katherine Harris
Chief Development Officer | Board Director
Katherine Harris is a prominent figure in the field of antibody research and development, currently serving as a Board Member of The Antibody Society. Here's a comprehensive overview of her professional background and involvement with the organization:
Professional Experience
Katherine Harris is currently the Chief Development Officer (CDO) at Rondo Therapeutics, a position she has held since February 2023.3 In this role, she:
- Leads IND-enabling activities, including CMC, toxicology, pharmacology, DMPK, and regulatory aspects
- Provides strategic guidance on target selection and program prioritization
- Oversees non-clinical development plans from candidate nomination through IND submission
- Manages external partnerships related to non-clinical development
Prior to her current position, Harris held several leadership roles in the biotechnology industry:
- Vice President of Discovery at Amgen (October 2021 - February 2023)
- Vice President and Senior Director of Discovery at Teneobio, Inc. (2017 - 2021)
- Senior Research Scientist at Teneobio, Inc. (2015 - 2017)
- Research Scientist at Panoply Bio and SwitchGear Genomics (2011 - 2015)
Education
Harris holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley (2001-2007) and a B.S. in Biology from the University of Missouri-Kansas City (1999-2000).3
Involvement with The Antibody Society
Katherine Harris has been actively involved with The Antibody Society in various capacities:
-
Board Member: Recently elected to the Board of Directors of The Antibody Society.56
-
Vice President: Serving as the Vice President of The Antibody Society for the 2024-25 term.1
-
Meetings Committee Chair: Harris chairs the Meetings Committee of The Antibody Society.27
-
Scientific Advisor: She serves as a scientific advisor for the Antibody Engineering & Therapeutics Europe conference.2
In her role with The Antibody Society, Harris contributes to the organization's mission of advancing antibody research and development. Her expertise in IND-enabling activities and preclinical drug development is particularly valuable to the society's goals.45
Katherine Harris's LinkedIn username is indeed "katharris".3
Highlights
The Antibody Society is hiring!
I'm honored to be speaking at Antibody Engineering & Therapeutics US 2024 this December in San Diego! 🎉
I’ll be presenting on Rondo Therapeutics’ innovative CD28 bispecific platform for solid tumors and co-chairing the Antibody-based Protein Degraders session with Dr. Jamie Spangler. The scientific advisory board from The Antibody Society has partnered with Informa to put together a truly exceptional scientific program and I am very excited to contribute to this premier event.
Secure your pass by July 12th to save up to $1,100! To join me with an additional 10% off the currently advertised rate, click here: https://lnkd.in/gr9GxqCu
Don’t miss this opportunity to be part of groundbreaking discussions and advancements in antibody engineering!
#AntibodyEngineering #Therapeutics #RondoTherapeutics #Biotech #Conference #TheAntibodySociety Informa Connect
